These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Intermolecular cross-linking of DNA through bifunctional intercalation of an antitumor antibiotic, luzopeptin A (BBM-928A).
    Author: Huang CH, Mirabelli CK, Mong S, Crooke ST.
    Journal: Cancer Res; 1983 Jun; 43(6):2718-24. PubMed ID: 6303566.
    Abstract:
    A bifunctional intercalator may intercalate with DNA in at least two ways. Both intercalating moieties may intercalate with the same DNA molecule (type I, intramolecular cross-linking) or with two separate DNA molecules (type II, intermolecular cross-linking). Production of type I is often assumed. Type II biintercalation has been suggested, but no direct evidence has been reported. In the present study, endonuclease-restricted PM2 phage or pBR322 plasmid DNA fragments were treated with the bifunctional intercalative antitumor antibiotics, luzopeptin A (BBM-928A) and echinomycin, and analyzed by agarose gel electrophoresis. Luzopeptin A treatment produced additional DNA bands which were the products of type II biintercalation. The types of restriction fragments involved were identified. Maximal type II biintercalation occurred at a luzopeptin A/DNA range of 0.14 to 0.18, at which more than 50% of the total DNA molecules were involved. Type II products were converted gradually to type I products upon prolonged incubation at 37 degrees, probably due to the tendency for intermolecular bonds to disrupt. Echinomycin treatment failed to produce type II products, probably because of a DNA-binding affinity weaker than that of luzopeptin A. Thus, it is possible to use the present gel system to demonstrate the type II biintercalation for strong biintercalators, but milder systems are needed for weak biintercalators.
    [Abstract] [Full Text] [Related] [New Search]